Browse > Article

A Comparative Analysis of the Systems Related to the Production, Authorization, and Listing for Insurance of Herbal Medicine Products in South Korea and Taiwan  

Son, Chi-Hyoung (Department of Health Science, Graduate School of Applied Eastern Medicine, Kyung Hee University)
Lim, Sabina (Department of Health Science, Graduate School of Applied Eastern Medicine, Kyung Hee University)
Lee, Eun-Kyoung (Research Institute of Korean Medicine Policy, The Association of Korean Medicine)
Kim, Dong-Su (Research Institute of Korean Medicine Policy, The Association of Korean Medicine)
Kim, Yun-Gi (Oriental Medicine, Kyung Hee University)
Cheng, Huan-Chiang (Department of Acupuncture, China Medical University Hospital Taipei Branch)
Kim, Yong-Ho (Department of Special Treatment, Daegu Oriental Hospital of Daegu Haany University)
Publication Information
The Journal of Korean Medicine / v.33, no.3, 2012 , pp. 147-159 More about this Journal
Abstract
Objectives: Systems related to the production, authorization, and listing for insurance of herbal medicine products were compared between South Korea and Taiwan to illuminate herbal medicine products system issues in South Korea. Methods: Papers, and laws and policies related to the production, authorization, and listing for insurance of herbal medicine products in South Korea and Taiwan are analyzed to create the primary documents. The documents from South Korea were screened with the advice of a specialist, while those from Taiwan have been verified through local investigation and with the help of a related specialist. The screened documents were then compared and analyzed in the order of the systems related to the production, authorization, and listing for insurance of herbal medicine products. Results: The systems related to the production of herbal medicine products satisfy GMP requirements in both countries, while Taiwan has more specialized systems related to the production of herbal medicine products and a more strict authorization program as compared to South Korea. While South Korea has most of the herbal medicine products classified as non-prescription drugs, Taiwan has them as prescription drugs. And while South Korea does not allow new herbal medicine products to be listed for insurance, Taiwan allows for once-a-year application toward listing for insurance. Conclusions: In order to ensure the safe and effective use of herbal medicine products, systems related to the production, authorization, and listing for insurance of herbal medicine products are to be established, while the categorization of medicine products principally used by Korean medicine doctors should be prepared. Furthermore, prescription by a Korean medicine doctor for new drugs made with natural products and their listing for insurance need to be encouraged.
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Korea Food & Drug Administration. The study on development of clinical trial guideline for herbal medicine. Seoul:Korea Food & Drug Administration. 2007:117.
2 Ministry of Health & Welfare, Korea Institute of Oriental Medicine. The study on the development ways of Korean herbal industry and economic analysis. Ministry of Health & Welfare. 2004:82-84.
3 Committee on Chinese Medicine and Pharmacy, Department of Health. Laws and Regulations on Management of Chinese Medicine Products in Taiwan. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2006:1-363.
4 Committee on Chinese Medicine and Pharmacy, Department of Health. Laws and Regulations on Management of Chinese Medicine and Pharmacy. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2005:425-598.
5 Committee on Chinese Medicine and Pharmacy, Department of Health. Indicators on Chinese Medicine Administration. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2010:13-27,45.
6 Committee on Chinese Medicine and Pharmacy, Department of Health. The compilation directing manual of the training exact effect for the Traditional Chinese Medicine GMP factories. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2008:11-249.
7 CENTRAL INTELLIGENCE AGENCY(CIA). Available at: URL: https://www.cia.gov. Accesse d July 10. 2011.
8 IMF statistics, Available at: URL: http://www.im f.org. Accessed July 10. 2011.
9 Department of Health. 2008 Statistics of General Health. Taipei:Department of Health. 2009:2-5.
10 Statistics Korea. Available at: URL: http://kostat. go.kr/portal/english/index.action. Accessed July 2011
11 Department of Health. 2008 The Statistical Annual Report of Medical Care Institution's Stataus & Hospital's Utilization. Taipei: Department of Health. 2009:340-343.
12 Ministry of Health & Welfare. The Second Plan of Korean Medicine Development 2011-2015. Seoul:Ministry of Health & Welfare. 2011:15.
13 GLOBAL HEALTH CARE. Production & Distribution of Herbal Medicine(I). Seoul: GLOBAL HEALTH CARE. 2011:32-33.
14 Pusan National University, School of Korean Medicine, Korea Institute of Oriental Medicine, The Association of Korean Oriental Medicine. 2009 Yearbook of Oriental Meidicine in Korea. Pusan National University School of Korean Medicine, Korea Institute of Oriental Medicine, The Association of Korean Oriental Medicine. 2010:164,190-191.
15 Paik WH. Studies on the Improvement of GMP Regulation for Herbal Preparations. Seoul:Korea Food & Drug Administration. 2006:13.
16 The Association of Korean Oriental Medicine. Korean Medicine National Health Insurance Payment. Seoul:The Association of Korean Oriental Medicine. 2011:67.
17 Lee EK. Chater 4, The study on Improvement in System for revitalization of Herbal formulation. In: Kim Yunkyoung. The Study on Standardization of Herbal formulation. Korea Food & Drug Administration. 2011.
18 Korea Institute of Oriental Medicine. 2008 The Survey on the usage pattern of Oriental medicine. Seoul:Ministry of Health&Welfare. 2009:421-429.
19 Ohno K , Sekiya N , Namiki T , Kasahara Y, Chino A, Hirasaki Y, et al. Effects of Kampo Therapy for Inpatient on Medical Economics. Kampo Med. 2011;62(1):29-33.   DOI
20 Ogawa K, Oka H, Huji N. Cost-Effectiveness Analysis of Sho-saiko-to Therapy in the Liver Cirrhosis. Jpn Pharmacol Ther 1995;23(8):343-351.
21 Akase T, Akiba T, Isai H. Suzuki S. A Pharmacoepidemiological and Economic Study on the Medicinal Expenses for the Treatment of Colds. Kampo Med. 2000;50(4):655-663.   DOI
22 Korea Institute for Industrial Economics and Trade. The Research of China market system. Korea Institute for Industrial Economics and Trade. 2010;1-5.
23 Korea Institute of Oriental Medicine. Usage Pattern of Kampo Medicine in Japan In Japan Kampo Medicine trends. Korea Institute of Oriental Medicine e-brief.
24 Korea Food & Drug Administration. A study on the revaluation method of medicinal herb preparations. Seoul:Korea Food & Drug Administration. 2004:49-87.
25 The Bureau of National Health Insurance. Global Budget system. Taipei:The Bureau of National Health Insurance. 2011:9.
26 GLOBAL HEALTH CARE. Production & Distribution of Herbal Medicine(I). Seoul: GLOBAL HEALTH CARE. 2011:51.
27 Committee on Chinese Medicine and Pharmacy, Department of Health. Yearbook of Herbal Medicine Industry 2009. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2009:32,45.
28 Pusan National University School of Korean Medicine, Korea Institute of Oriental Medicine, The Association of Korean Oriental Medicine. 2009 Yearbook of Oriental Medicine in Korea. Pusan National University School of Korean Medicine, Korea Institute of Oriental Medicine, The Association of Korean Oriental Medicine. 2010:164.
29 Committee on Chinese Medicine and Pharmacy, Department of Health. Yearbook of Herbal Medicine Industry 2009. Taipei: Committee on Chinese Medicine and Pharmacy, Department of Health. 2009:32,45.
30 Korea Institute of Oriental Medicine. The Polocy and Current Situation of Traditional Medicine in Taiwan. 1997.
31 Lee KG, Bae SH, Shin HK. An Investigaion about the Present States of Clinical Trial for Traditional Medicine in Korea, China, Taiwan and Japan.Korean Journal of Oriental Medicine. 2006:12(1):13-22.